AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
ATRCMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quar
AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation
ATRC(NASDAQ:ATRC) MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT™ device, an innovative cryoablation technology used to help manage post-operative pain following amputation procedures. Each year, over 185,000 amputations occur in the U.S., with approximately 60%1 of patients experiencing residual
AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference
ATRCMASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2025 Wells Fargo Healthcare Conference. AtriCure’s management is scheduled to participate in a fireside chat on Wednesday, September 3, 2025, at 3:45 p.m. Eastern Standard Time. Interested parties may a
UBS Maintains Buy on AtriCure, Lowers Price Target to $58
ATRCJMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target
ATRC14 Analysts Assess AtriCure: What You Need To Know
ATRCNeedham Maintains Buy on AtriCure, Lowers Price Target to $44
ATRCAtriCure Raises FY2025 Adj EPS Guidance from $(0.64)-$(0.57) to $(0.55)-$(0.50) vs $(0.66) Est; Affirms FY2025 Sales Guidance of $517.00M-$527.00M vs $522.79M Est
ATRCAtriCure Q1 Adj. EPS $(0.14) Beats $(0.23) Estimate, Sales $123.62M Beat $122.92M Estimate
ATRCAtriCure Earnings Preview
ATRCCitizens Capital Markets Reiterates Market Outperform on AtriCure, Maintains $60 Price Target
ATRCCanaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $52
ATRCJP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $46
ATRCNeedham Reiterates Buy on AtriCure, Maintains $51 Price Target
ATRC11 Analysts Have This To Say About AtriCure
ATRCNeedham Reiterates Buy on AtriCure, Maintains $51 Price Target
ATRCAtricure Files For Mixed Shelf; Size Not Disclosed
ATRCOppenheimer Maintains Outperform on AtriCure, Raises Price Target to $45
ATRCPiper Sandler Maintains Overweight on AtriCure, Raises Price Target to $50
ATRCJMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target
ATRCStifel Maintains Buy on AtriCure, Raises Price Target to $48
ATRCNeedham Reiterates Buy on AtriCure, Maintains $51 Price Target
ATRCCanaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $66
ATRCAtriCure Sees FY25 Adj. EPS ($0.57)-($0.64); Revenue $517M-$527M.
ATRCAtriCure Q4 2024 Adj. EPS $(0.08) Beats $(0.23) Estimate, Sales $124.300M Beat $121.842M Estimate
ATRCNeedham Reiterates Buy on AtriCure, Maintains $40 Price Target
ATRCAtriCure Announces Q4 2024 Preliminary Revenue Of $124.3M, Up 17%, And FY Revenue Of $465.3M, U.S. Revenue Up 14% To $101.6M, International Revenue Increased 28% To $22.7M; Forecasted 2024 Adjusted EBITDA Is $26M-$29M And Adjusted Loss Per Share Is $0.74-
ATRCAtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target
ATRCNeedham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged.
4 Analysts Have This to Say About AtriCure
ATRCOver the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Needham Maintains Buy on AtriCure, Lowers Price Target to $67
ATRCSVB Leerink Maintains Outperform on AtriCure, Lowers Price Target to $75
ATRCAtriCure: Q1 Earnings Insights
ATRCAtriCure (NASDAQ:ATRC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM.
Here's what investors need to know about the announcement.
Earnings
AtriCure missed estimated earnings by 3.13%, reporting an EPS of $-0.33 versus an estimate of $-0.32.
AtriCure Sees FY22 Adj. EPS $(1.12)-$(1.07) Vs. $(1.05) Est., Sales $318M-$330M Vs. $321.65M Est.
ATRCAtriCure Q1 EPS $(0.33) Misses $(0.32) Estimate, Sales $74.60M Beat $71.17M Estimate
ATRC